However, it should be noted that, according to our results, an unassigned species of the genus Candida with significantly increased abundance in HCC group could not be further explored as it has not been identified
Another GLP-1 ETF With a Passive Approach An alternative in the GLP-1 ETF space is the Amplify Weight Loss Drug & Treatment ETF (NYSEARCA: THNR)
Some areas are quick and straightforward, while others require more time, skill, and precision, which naturally affects the price
Evidence references ADJUNCT ONE, PMID 27506222 ADJUNCT TWO, PMID 27493132 ADJUST T1D, PMID 40550013 Semaglutide crossover study, PMID 39794615 Tirzepatide observational data (Shah 2024), PMC11571402 Shah discontinuation post-hoc (ADJUNCT I/II), PMID 39717993 Shah 2025, GLP-1RA / tirzepatide in T1D with severe early (genetic) obesity ( JDST ) Insulin titration paper, PMID 39829697 Adjunct therapy review, PMID 40618954 Bone health review, PMC8118128 Weight loss and bone, PMID 38916894 Consensus and guidelines: ADA Standards 2025, PMID 39651989 ISPAD 2024, PMID 39657603 GLP-1 AID consensus, PMID 39517127 Related reading on GNL This Episode 17 conversation was the inspiration for the four-part Adjunctive Therapies guide built on top of the April 2026 evidence update
